Project Grant R56EY035213
Award Date 9/1/23
Completion Date 8/31/24
Dollars Obligated $583K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $295,500.00 to The Schepens Eye Research Institute, Inc. to develop a neuropeptide-based countermeasure to mitigate ocular damage from exposure to mustard gas agents. The research aims to assess the therapeutic efficacy of topical alpha-melanocyte-stimulating hormone (α-MSH) treatment in preventing corneal damage, nerve loss, and inflammation in a mouse model of...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program provides $498,248 to the University of Connecticut Health Center (UCHC) to investigate the molecular mechanisms underlying corneal and retinal injury caused by exposure to chemical threat agents like nitrogen mustard. The key objectives are to: 1) Examine the role of the p53-PAD axis in driving corneal hypercitrullination, a pathological response, after nitrogen...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will provide $937,468 to Northwestern University to understand the pathological mechanisms of sulfur mustard gas keratopathy (MGK) in the cornea. The research aims to explore how corneal mustard exposure induces autophagy, a cellular process that can play detrimental roles, via liberating the protein Beclin1 from the Beclin1-Bcl2 complex. The project will conduct in vitro and in...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,467,198.00 to the University of Connecticut Health Center (UCHC) to investigate the cellular and molecular mechanisms of corneal and sensory nerve damage caused by exposure to chemical warfare agents. The key products and services to be delivered under this 3-year award, which runs from September 15, 2025 to August...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,434,104 to the University of Texas Medical Branch at Galveston (UTMB) to investigate the role of the protein SIRT6 in mitigating corneal and retinal injury caused by exposure to the highly toxic chemical acrolein. The 3-year project aims to characterize the pathological changes in the cornea and retina following acrolein exposure using a newly developed...
- This Cooperative Agreement award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop a novel fenofibrate-loaded microemulsion (FENO-ME) eyedrop as a non-steroid treatment for nitrogen mustard (NM)-induced corneal injury. The $22,677 award to Virginia Commonwealth University (VCU) spans from Sep 2025 to May 2030. The project seeks to: 1) Validate PPARα signaling as a drug target for NM-induced corneal injury and optimize the FENO-ME eyedrop formulation; 2)...
- The U.S. Defense Health Agency awarded a $1,466,706 Project Grant to The Schepens Eye Research Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to develop topical oxygen treatments for severe chemical eye injuries, with the goal of providing pan-ocular protection. As a non-profit research organization affiliated with Harvard Medical School and Massachusetts Eye and Ear, Schepens Eye Research Institute has an extensive portfolio...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,477,500 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The 3-year grant, awarded on September 1, 2023, will fund research on "Topical Calcitonin Gene-Related Peptide for Corneal Injury Prevention and Regeneration." The Schepens Eye Research Institute, which has...
- The Schepens Eye Research Institute, Inc. was awarded a $1,475,676 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2025 to develop concomitant topical treatments for pain and inflammation resulting from ocular injuries. The Military Medical Research and Development program supports biomedical research that transforms military and public health...
- This $1,559,917 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to develop a topical neurokinin-1 receptor (NK1R) antagonist as a non-addictive analgesic treatment for chronic ocular pain. The key objectives are to assess the analgesic efficacy of the NK1R antagonist and determine its effects on the ocular surface-trigeminal ganglion neurosensory pathway. The project is...